Workflow
ProKidney(PROK)
icon
Search documents
ProKidney to Participate in the Jefferies Global Healthcare Conference
globenewswire.com· 2024-05-29 11:00
The ProKidney management team will host one-on-one meetings during the event. Interested investors should contact their Jefferies representative to schedule meetings. WINSTON-SALEM, N.C., May 29, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) ("ProKidney"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced that senior members of the management team will be participating in the Jefferies Global Healthcare Conference taking place from ...
ProKidney to Host Virtual KOL Event to Discuss Current Treatment Landscape of Chronic Kidney Disease Caused by Diabetes and Data from Phase 2 RMCL-002 Clinical Trial on May 28, 2024
Newsfilter· 2024-05-21 11:00
Arnold L. Silva, MD, PhD is the director of the Home Hemodialysis and Peritoneal Dialysis programs at Boise Kidney & Hypertension Institute. Dr. Silva received his bachelor's and master's degrees in Biology from California State University in Fresno, CA. He received his PhD from the University of Arizona in Tucson, studying the physiology of membrane transport and cell volume regulation. He received his MD from the University of Arizona, followed with residency training in internal medicine and nephrology f ...
ProKidney to Host Virtual KOL Event to Discuss Current Treatment Landscape of Chronic Kidney Disease Caused by Diabetes and Data from Phase 2 RMCL-002 Clinical Trial on May 28, 2024
globenewswire.com· 2024-05-21 11:00
WINSTON-SALEM, N.C., May 21, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) ("ProKidney" or the "Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), will host a virtual KOL event on Tuesday, May 28, 2024 at 8:00 AM ET, featuring Steven G. Coca, DO, MS (Icahn School of Medicine at Mount Sinai) and Arnold L. Silva, MD, PhD (University of Arizona) who will discuss the unmet medical need and current treatment landscape for patients with modera ...
ProKidney(PROK) - 2024 Q1 - Quarterly Report
2024-05-10 20:03
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40560 ProKidney Corp. (Exact Name of Registrant as Specified in its Charter) | Cayman Islands | 98-1586514 | | --- | --- | | ( St ...
ProKidney(PROK) - 2024 Q1 - Quarterly Results
2024-05-10 11:05
Exhibit 99.1 ProKidney Reports Business Updates and First Quarter 2024 Financial Results Clinical Updates • Final results from RMCL-002 Phase 2 trial to be presented in the Late Breaking Clinical Trials session at the European Renal Association (ERA) Congress on May 25, 2024. An investor call to provide a perspective on CKD with Dr. Arnold Silva and Dr. Steven Coca and a recap of the RMCL-002 data is planned for May 28, 2024 • On schedule to resume manufacturing and PROACT 1 Phase 3 trial, commence PROACT 2 ...
ProKidney(PROK) - 2023 Q4 - Annual Results
2024-03-22 00:00
Exhibit 99.1 ProKidney Reports Full Year 2023 Financial Results and Recent Corporate Highlights WINSTON-SALEM, N.C., March 21, 2024 -- ProKidney Corp. (Nasdaq: PROK) ("ProKidney" or the "Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced financial results for the year ended December 31, 2023. "We are very excited about the future of ProKidney. Building on the positive interim Phase 2 data that we released last Fall for rilparencel ...
ProKidney Reports Full Year 2023 Financial Results and Recent Corporate Highlights
Newsfilter· 2024-03-21 23:49
WINSTON-SALEM, N.C., March 21, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (NASDAQ:PROK) ("ProKidney" or the "Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced financial results for the year ended December 31, 2023. "We are very excited about the future of ProKidney. Building on the positive interim Phase 2 data that we released last Fall for rilparencel (which we sometimes refer to as REACT®) demonstrating the potential to preserve ...
ProKidney(PROK) - 2023 Q4 - Annual Report
2024-03-21 23:36
FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40560 ProKidney Corp. Registrant's telephone number, including area code: (336) 999-7028 Securities registered pursuant to Section 12 ...
ProKidney(PROK) - 2023 Q3 - Earnings Call Transcript
2023-11-16 21:40
ProKidney Corp. (NASDAQ:PROK) Q3 2023 Results Conference Call November 14, 2023 8:00 AM ET Company Participants Dr. Glenn Schulman - SVP of IR Pablo Legorreta - Chairman of Board Dr. Tim Bertram - Co-Founder and Member of Scientific Advisory Board Dr. Bruce Culleton - Chief Executive Officer Conference Call Participants Yigal Nochomovitz - Citi Justin Zelin - BTIG Jonathan Miller - Evercore Jason Gerberry - Bank of America Operator Good morning, ladies and gentlemen, and welcome to the ProKidney Corporate U ...
ProKidney(PROK) - 2023 Q3 - Quarterly Report
2023-11-13 16:00
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40560 ProKidney Corp. (Exact Name of Registrant as Specified in its Charter) | Cayman Islands | 98-1586514 | | --- | --- | | ...